A Silent Surge: The Decline of Hepatitis C Antiviral Treatment Undermines U.S. Eradication Goals
Despite the development of revolutionary antiviral treatments capable of curing over 95% of hepatitis C cases, a concerning trend has emerged in the United States: the number of patients receiving these life-saving therapies has markedly decreased in recent years. A comprehensive analysis led by Dr. Sanjay Kishore at the University of Virginia School of Medicine, in collaboration with researchers from Mass General Brigham, uncovered an alarming decline in prescriptions of direct-acting antivirals (DAAs) for hepatitis C since their peak in 2015. This retreat threatens to undercut national efforts aimed at eliminating hepatitis C as a public health threat.
Hepatitis C virus (HCV) is a bloodborne pathogen primarily targeting the liver, where it can induce chronic infection that progressively damages hepatic tissue. Transmission in the U.S. predominantly occurs through injectable drug use, yet perinatal transmission and, less commonly, sexual transmission also contribute to incidence rates. The insidious nature of HCV lies in its often asymptomatic early course. Symptoms like jaundice, fatigue, nausea, and fever typically manifest only after substantial liver injury has developed, delaying diagnosis for millions. Estimates suggest that approximately four million Americans harbor chronic hepatitis C infections, many undiagnosed and untreated.
Direct-acting antivirals, introduced a decade ago, revolutionized the management of HCV by targeting specific viral proteins critical for replication. These agents boast cure rates exceeding 95%, offering the possibility of viral eradication with minimal side effects compared to previous interferon-based regimens. Their widespread adoption initially showed promise in bending the epidemiological curve of hepatitis C, with prescription numbers soaring shortly after their 2013 introduction and peaking at over 185,000 courses in 2015.
However, post-2015, a puzzling inversion occurred. The robust momentum in initiating antiviral therapies diminished year-over-year, bottoming out at fewer than 70,000 treatment courses in 2025. Early treatment uptake was concentrated among older adults and those with Medicare or private insurance coverage, reflecting disparities in healthcare access. Notably, Medicaid policies initially imposed restrictions limiting antiviral prescriptions to patients with advanced liver fibrosis. While usage among Medicaid recipients increased between 2016 and 2019 as some restrictions eased, a significant drop-off ensued, possibly exacerbated by the COVID-19 pandemic’s disruption of healthcare services.
This downward trajectory in antiviral deployment is troubling, given that the incidence of new hepatitis C infections remains stubbornly high or may even be rising in certain demographics. Dr. Benjamin Rome of Mass General Brigham emphasizes that suboptimal treatment rates may in part explain the stasis in reducing HCV prevalence. The shortfall imperils the federal goal of eliminating hepatitis C by necessitating an estimated 260,000 treatment courses annually to interrupt transmission chains effectively and prevent long-term complications such as cirrhosis and hepatocellular carcinoma.
Addressing this multifaceted challenge demands systemic reforms beyond enhanced screening programs. Recommendations arising from the research suggest implementing same-day treatment initiation protocols to reduce barriers between diagnosis and therapy commencement. Expanding telehealth platforms and deploying mobile outreach services could bridge gaps in reaching marginalized populations disproportionately affected by HCV. Additionally, structural financing reforms like those proposed in the Cure Hepatitis C Act of 2025 aim to alleviate economic constraints that hinder access to these medications.
The stakes extend beyond individual health outcomes; untreated hepatitis C imposes substantial burdens on healthcare infrastructure through costly hospitalizations, liver transplantations, and cancer treatments. The economic ramifications ripple through public health budgets and social systems, underscoring the urgency of reinvigorating treatment efforts. Advocates like Dr. Kishore contend that proactive state-level commitments, exemplified by Virginia’s aspirations to eliminate hepatitis C, can serve as beacons for national strategies, leveraging political will and resource allocation to close existing treatment gaps.
Nonetheless, eradicating hepatitis C presents scientific and logistical complexities. Persistent viral reservoirs and reinfection risks require ongoing vigilance, while social determinants such as stigma, socioeconomic disparities, and healthcare inequities must be addressed concurrently. Robust epidemiological surveillance and tailored interventions informed by granular data are critical to adapting strategies dynamically. Ultimately, the promise of DAAs can only be fully realized through comprehensive, coordinated public health initiatives encompassing prevention, diagnosis, and uninterrupted treatment access.
The findings of this pivotal analysis were published in the Journal of the American Medical Association (JAMA), with contributions from Margaret Hayden, Micah Johnson, Aaron S. Kesselheim, and Benjamin Rome alongside Dr. Kishore. Supported by a grant from Arnold Venture, the study casts a clarion call to the medical community and policymakers alike. It highlights the mandatory synergy between advances in pharmaceutical innovation and healthcare delivery reforms to surmount remaining barriers.
While legislative action at the federal level may be pending, local and state healthcare systems are empowered to transcend inertia and pioneer solutions. Enhanced education campaigns, integration of hepatitis C care into primary care settings, and incentivization models for providers to initiate and complete treatment courses are practical pathways. Harnessing the momentum of technological advancements alongside policy innovation could reverse the disturbing trend and place the nation back on track toward fulfilling the ambitious but achievable goal of hepatitis C elimination.
In this critical juncture for infectious disease control, a proactive stance marrying cutting-edge antiviral therapy with systemic access improvements is paramount. The story of hepatitis C in America serves as both a cautionary tale about the perils of complacency and an inspiring blueprint for harnessing medical breakthroughs toward tangible public health victories. Addressing the decline in antiviral prescriptions is not merely a medical imperative but a societal responsibility, necessitating cohesive action to rescue millions from the shadow of a curable yet deadly virus.
Subject of Research: Hepatitis C treatment trends and public health implications
Article Title: Not provided
News Publication Date: Not provided
Web References: https://dx.doi.org/10.1001/jama.2026.3328
References: Kishore et al., Journal of the American Medical Association, 2026
Image Credits: Not provided
Keywords: Hepatitis C, direct-acting antivirals, antiviral treatment, viral hepatitis, liver disease, infectious diseases, public health, healthcare disparities, pharmacoeconomics, disease elimination, viral eradication, drug therapy
